The Center for Breakthrough Medicines (CBM) has entered into an agreement with BioAnalysis LLC (BIA) to provide CBM’s clients with direct access to BIA’s advanced testing capabilities, including characterization of viral vectors using BIA’s proprietary sedimentation velocity approach to analytical ultracentrification (SV-AUC), as well as other advanced biophysical methods and analytics. Dr. Lake Paul, founder and principal scientist at BIA, is regarded as a leader in the field and is frequent...